Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$4.49
$0.08(1.81%)
At close: 4:00 PM EDT
$4.49
$0.08(1.81%)
Day’s Range― - ―
52-Week Range$3.64 - $49.51
Previous CloseN/A
Volume8.49K
Average Volume (3M)557.82K
Market Cap
$41.48M
Enterprise Value$38.83
Total Cash (Recent Filing)$1.08M
Total Debt (Recent Filing)$3.04M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding6,511,540
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lower Debt BurdenDebt reduction lowers fixed financing obligations compared with 2022–2023 and may reduce balance-sheet pressure while development continues. The benefit is meaningful, although negative equity and ongoing cash needs still constrain financial flexibility.
Loss Reduction Versus 2023The historical reduction in annual losses suggests some improvement in cost control or operating efficiency relative to 2023. This provides a modest fundamental positive, though the company remains unprofitable and TTM losses are still material.
Proprietary T-Cell PlatformA proprietary T-cell technology focus gives the company a differentiated research platform spanning viral infections and cancers. If development succeeds, the platform could support multiple therapies, although it remains pre-commercial and execution-dependent.
Bears Say
No Commercial RevenueZero revenue confirms that the business has not yet established commercial product sales or a self-funding operating model. Continued dependence on research progress and external capital increases the time and execution required to reach sustainable operations.
Persistent Cash BurnSustained negative operating and free cash flow means the company must continue funding research and corporate activities without internally generated cash. Unless revenue arrives or spending falls, recurring financing needs could create dilution or funding constraints.
Negative Equity And Limited CushionNegative equity and a small asset base leave limited balance-sheet protection if losses continue. This weakens financial flexibility, makes additional funding more important, and increases the potential impact of adverse development or financing outcomes.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $3.64 and its highest was $49.51 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $41.48M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 94 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Aug 13, 2026. The company reported -$1.525 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 6,511,540 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.525 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.546%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―
Ownership Overview
66.02% Insiders
0.71% Mutual Funds
<0.01% Other Institutional Investors
33.01% Public Companies and
Individual Investors